Common TDP1 polymorphisms in relation to survival among small cell lung cancer patients: a multicenter study from the International Lung Cancer Consortium

BACKGROUND: DNA topoisomerase inhibitors are commonly used for treating small cell lung cancer (SCLC). Tyrosyl-DNA phosphodiesterase (TDP1) repairs DNA damage caused by this class of drugs and may therefore influence treatment outcome. In this study, we investigated whether common TDP1 single nucleo...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Cancer Res
Autors principals: Lohavanichbutr, Pawadee, Sakoda, Lori C., Amos, Christopher I., Arnold, Susanne M., Christiani, David C., Davies, Michael P.A., Field, John K., Haura, Eric B., Hung, Rayjean J., Kohno, Takashi, Landi, Maria Teresa, Liu, Geoffrey, Liu, Yi, Marcus, Michael W., O’Kane, Grainne M., Schabath, Matthew B., Shiraishi, Kouya, Slone, Stacey A., Tardón, Adonina, Yang, Ping, Yoshida, Kazushi, Zhang, Ruyang, Zong, Xuchen, Goodman, Gary E., Weiss, Noel S., Chen, Chu
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5732876/
https://ncbi.nlm.nih.gov/pubmed/28974547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1401
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars